Filing search / Incannex Healthcare Limited / "Recruitment"

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

to this, any drug-candidate-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result

S-1/A

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

Human Research Ethics Committee (“HREC”) for the conduct of the BA/BE clinical trial. As of April 2024 participant recruitment and dosing is ongoing … identical across the three arms of the trial. Patient recruitment commenced in August 2022 and dosing was completed in September 2022. The final clinical

S-1

IXHL Incannex Healthcare Limited

3 Jul 24

IPO registration

6:29am

/BE clinical trial. As of April 2024 participant recruitment and dosing is ongoing. Phase 2/3 clinical trial investigating IHL-42X in patients with OSA … participants (n = 36) received either IHL-675A, CBD or HCQ and the assessments were identical across the three arms of the trial. Patient recruitment

8-K

EX-99.1

IXHL Incannex Healthcare Limited

16 Apr 24

Incannex Healthcare Inc. Quarterly Update, Q1 2024

9:30am

with NCT number NCT05857384. Patient recruitment continued during the quarter, a total of 72 participants have been randomised and received a minimum

8-K

EX-99.1

IXHL Incannex Healthcare Limited

17 Jan 24

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

6:05am

protocol, informed consent procedures, recruitment materials, and participant risk versus benefit analysis. The RePOSA Clinical Trial The RePOSA study

6-K

EX-99.1

yrzsyhl94i0hp 26fv

26 Oct 23

Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

6:02am

6-K

EX-99.1

tdar eaf4nlvhz8vufof

1 Sep 23

Report of Foreign Private Issuer

12:00am

6-K

EX-99.1

w28xvr52qiufbbd2tht

18 Jul 23

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

6:04am

6-K

EX-99.1

zatzx0k

13 Jul 23

Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

6:02am

6-K

EX-99.1

zx5kc87imb0ryzn1r

5 Jul 23

Report of Foreign Private Issuer

8:47pm

6-K

EX-99.1

iwnhv3i0twi2ck

15 Jun 23

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

9:06pm

20-F

bzw8acr

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

14o2aann4l2 vrtc

19 Sep 22

Report of Foreign Private Issuer

9:38pm

6-K

EX-99.1

skubi 2mv5fs

9 Aug 22

Report of Foreign Private Issuer

6:01am

6-K

EX-99.1

5c4oy0

28 Jul 22

Incannex Healthcare Quarterly Activities Report and Appendix 4C

2:35pm

6-K

EX-99.1

13gj60uzis43j 1uriw

21 Jul 22

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

6:02am

6-K

EX-99.1

2zzzwz

28 Jun 22

Report of Foreign Private Issuer

6:52pm

6-K

EX-99.1

spbld

28 Apr 22

Quarterly Activities Report and Appendix 4C Cash Flow Statement

6:40am